Truist Financial
HRTX icon

Truist Financial’s Heron Therapeutics HRTX Stock Holding History

Truist Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,226
Closed -$109K – 2791
2021
Q3 		$109K Sell
10,226
-7,675
-43% -$93.4K ﹤0.01% 2641
2021
Q2 		$278K Buy
17,901
+300
+2% +$4.77K ﹤0.01% 2412
2021
Q1 		$285K Buy
17,601
+1,150
+7% +$20.5K ﹤0.01% 2319
2020
Q4 		$348K Buy
16,451
+1,400
+9% +$24.3K ﹤0.01% 2063
2020
Q3 		$223K Sell
15,051
-6,500
-30% -$101K ﹤0.01% 2202
2020
Q2 		$317K Buy
21,551
+1,101
+5% +$18.1K ﹤0.01% 1910
2020
Q1 		$240K Buy
20,450
+2,895
+16% +$54.4K ﹤0.01% 2009
2019
Q4 		$412K Buy
+17,555
New +$388K ﹤0.01% 1985

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Truist Financial's HRTX Position: Q4 2021 in Review

Truist Financial sold out of Heron Therapeutics (HRTX) in Q4 2021, closing a stake of 10,226 shares — an estimated $109K sold.

Truist Financial first reported a position in HRTX in Q4 2019 and held it in 8 quarters. The position peaked at $412K in Q4 2019. 200 funds tracked by Wall St. Rank hold HRTX as of Q4 2021.

  • Truist Financial reported no remaining Heron Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Truist Financial sold 10,226 Heron Therapeutics shares in Q4 2021, an estimated $109K.
  • Truist Financial first reported a position in Heron Therapeutics in Q4 2019 and held it in 8 quarters.
  • Truist Financial's Heron Therapeutics position peaked at $412K in Q4 2019.
  • 200 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2021.

Based on Truist Financial's 13F filing for Q4 2021, filed 14 Feb 2022.